The bladder cancer market is projected to reach $16 billion across 8 major markets (8MM) by 2033, driven by new therapies and ...

Three Motley Fool contributors think they've found unstoppable dividend stocks to buy right now. Here's why they picked ...

"Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since ...

While this new treatment offers a vital lifeline, experts are simultaneously stressing the critical importance of recognising ...

AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, rising 4.2% year over year ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

Excitement is building as a new treatment for advanced bladder cancer that doubles survival time has been approved for NHS ...

Experts said the approval of the new treatment combination would bring a ‘fundamental shift’ in care for patients with ...

Pfizer is making significant strides in the oncology sector, boasting a robust lineup of cancer treatments. Its oncology ...

Pfizer Inc. just got a price target bump from Citi. Following a robust Q2, Citi upgraded Pfizer's price target from $25 to ...